1. Home
  2. CRCT vs TBPH Comparison

CRCT vs TBPH Comparison

Compare CRCT & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cricut Inc.

CRCT

Cricut Inc.

HOLD

Current Price

$5.60

Market Cap

913.1M

Sector

Industrials

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$17.06

Market Cap

908.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRCT
TBPH
Founded
1969
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Wholesale Distributors
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
913.1M
908.9M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
CRCT
TBPH
Price
$5.60
$17.06
Analyst Decision
Strong Sell
Buy
Analyst Count
1
6
Target Price
$3.00
$18.40
AVG Volume (30 Days)
606.5K
350.2K
Earning Date
05-05-2026
05-04-2026
Dividend Yield
22.20%
N/A
EPS Growth
20.69
279.13
EPS
0.28
N/A
Revenue
$708,780,000.00
$15,386,000.00
Revenue This Year
$0.08
$8.46
Revenue Next Year
$0.98
N/A
P/E Ratio
$20.20
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.74
$13.08
52 Week High
$6.90
$21.03

Technical Indicators

Market Signals
Indicator
CRCT
TBPH
Relative Strength Index (RSI) 51.00 57.90
Support Level $5.35 $16.80
Resistance Level $5.98 $17.11
Average True Range (ATR) 0.18 0.05
MACD -0.03 -0.01
Stochastic Oscillator 40.91 21.57

Price Performance

Historical Comparison
CRCT
TBPH

About CRCT Cricut Inc.

Cricut Inc designs and builds a creativity platform that enables users to turn ideas into professional-looking handmade goods. With its connected machines, design apps and accessories, and materials, the users create everything from personalized birthday cards, mugs and T-shirts to large-scale interior decorations. It has two segments including the Platform segment which derives revenue from monthly and annual subscription fees, purchases of digital content, and a minimal amount of the revenue allocated to unspecified future upgrades and enhancements related to the essential software and access to the Company's cloud-based services and Products segment which derives revenue from the sale of its connected machine hardware, and sale of craft, DIY, home decor products and extensions.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.

Share on Social Networks: